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Site a Is Crucial for Two Routes of IFNg-Induced
MHC Class I Transactivation: The ISRE-Mediated
Route and a Novel Pathway Involving CIITA
Sam J. P. Gobin, Ad Peijnenburg, Vivian Keijsers, MHC class I heavy chain, it also enhances the expres-
sion of b2m, TAP1, TAP2, LMP2, and LMP7 (Gussow etand Peter J. van den Elsen
al., 1987; Yang et al., 1992; Wright et al., 1995; Min etDepartment of Immunohaematology and
al., 1996), all of which play an important role in MHCBlood Bank
class I±mediated antigen presentation (reviewed byUniversity Hospital Leiden
Lehner and Cresswell, 1996; Marusina and Monaco,2333 ZA Leiden
1996). The IFNg induction pathway that leads to MHCThe Netherlands
class I transactivation is initiated by the binding of IFNg
to its receptor, which then leads to the activation of the
tyrosine kinases JAK1 and JAK2 (Schindler and Darnell,
Summary 1995). These tyrosine kinases phosphorylate the signal
transducer and activator of transcription-1a (STAT1a;
The constitutive and cytokine-induced levels of major also termed p91, STAT91, or GAF). STAT1a binds the
histocompatibility (MHC) class I expression are tightly g-activated site of genes, such as interferon regulatory
controlled at the transcriptional level. In this study, it factor-1 (IRF-1; Fujita et al., 1989; Harada et al., 1989,
is shown that the cis-acting regulatory element site a 1994), as a homodimer (Bluyssens et al., 1995; Schindler
of the MHC class I promoter is essential for the IFNg- and Darnell, 1995), inducing transcription of these IFNg-
induced transactivation of MHC class I gene expres- inducible genes. IRF-1 is the principal transcription fac-
sion through the ISRE. Moreover, it was discovered tor binding the ISRE in the MHC class I promoter (Chang
that the class II transactivator (CIITA), which is itself et al., 1992; Girdlestone et al., 1993; Johnson and Pober,
under the control of the IFNg induction pathway, 1994).
strongly transactivates MHC class I gene expression The regulatory element site a is homologous to the
and exerts its activity through site a. Therefore, site cAMP-response element (CRE) and is constitutively oc-
a is a crucial regulatory element, mediating the classic cupied in vivo, as demonstrated by footprinting experi-
route of IFNg induction via the ISRE as well as a novel ments (Korber et al., 1988; IsraeÈ l et al., 1989; Dey et al.,
route of MHC class I transactivation involving CIITA. 1992). Its role in MHC class I transactivation has not
been well characterized, but some studies have sug-
gested that site a may have a role in constitutive MHC
class I expression in lymphoid cells (Dey et al., 1992).
Introduction The recently identified class II transactivator (CIITA)
has been shown to be essential for transcriptional acti-
The expression of major histocompatibility (MHC) class vation of MHC class II genes (Steimle et al., 1993, 1994;
I molecules is essential in the immune response because Mach et al., 1996). MHC class II gene promoters contain
they present antigen-derived peptides to cytotoxic T a set of conserved regulatory elements, known as the
lymphocytes (Germain, 1994). In accordance with this S (W or Z), X1, X2, and Y boxes. These regulatory ele-
key role in antigen presentation, MHC class I molecules ments are bound by a number of DNA-binding proteins.
are ubiquitously expressed and their basal level of ex- These include the RFX protein complex, which binds
pression can be induced by a number of cytokines and the X1 box; X2BP and other Fos/Jun- and ATF/CREB-
viral factors (reviewed by Singer and Maguire, 1990; Ting related proteins, which bind the X2 box; and NF-Y, which
and Baldwin, 1993; Le Bouteiller, 1994). Expression of binds the Y box (reviewed by Benoist and Mathis, 1990;
MHC class I molecules is tightly regulated at the tran- Glimcher and Kara, 1992; Ting and Baldwin, 1993; Mach
scriptional level during development and also in fully et al., 1996). CIITA is thought to act as a coactivator and,
differentiated cells. since no DNA-binding motif has been found (Steimle et
The level of MHC class I gene expression is controlled al., 1993), CIITA is believed to exert its activity through
by transcription factors binding to cis-acting regulatory these DNA-binding proteins (Riley et al., 1995; Zhou and
elements within the MHC class I promoter. The main Glimcher, 1995; Mach et al., 1996). In particular, the S
control elements include enhancer A, the interferon- and X2 boxes and their DNA-binding proteins appear
stimulated response element (ISRE), and site a (re- to be crucial for mediating transactivation by CIITA
viewed by Ting and Baldwin, 1993; Le Bouteiller, 1994). (Zhou and Glimcher, 1995). CIITA contains several do-
Enhancer A is bound by transcription factors of the NF- mains involved in MHC class II transactivation: an
kB/rel family and is thought to be essential for constitu- N-terminal acidic domain with transactivation proper-
tive and cytokine-induced expression (reviewed by ties; a proline-, serine-, and threonine-rich domain; and
Baeuerle and Henkel, 1994; Le Bouteiller, 1994). The a C-terminal domain (Riley et al., 1995; Zhou and
ISRE is the target DNA-binding site for factors of the Glimcher, 1995). CIITA is constitutively expressed in
interferon regulatory factor (IRF) family, and it mediates MHC class II±positive cells such as B cells (Steimle et
the induction of MHC class I expression by type I and al., 1993). In other cell types, the expression of CIITA
type II interferons (reviewed by Schindler and Darnell, can be induced by IFNg and is under the control of the
1995). IFNg-mediated signal transduction pathway (Chang et
In particular, interferon-g (IFNg) is a potent inducer of al., 1994; Chin et al., 1994; Steimle et al., 1994; Lee and
Benveniste, 1996; Meraz et al., 1996). Therefore, MHCMHC class I membrane expression: in addition to the
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class II genes are inducible by IFNg, despite a lack of
ISRE and g-activated site elements in their promoter
region.
The importance of CIITA in the regulation of MHC
class II expression is illustrated in patients with MHC
class II deficiency, also referred to as bare lymphocyte
syndrome (BLS). In B-LCL and fibroblast cell lines from
patients belonging to BLS complementation group A,
the lack of MHC class II expression is caused by muta-
tions in the CIITA gene (reviewed by Mach et al., 1996).
As a result, these cells are thought to express mutated
or truncated forms of CIITA, which are not functional in
MHC class II transactivation. Transfection experiments
have shown that CIITAunder thecontrol of a constitutive
promoter was sufficient to induce MHC class II expres-
sion in these cell lines (Steimle et al., 1993, 1994). There-
fore, it was concluded that CIITA governs both constitu-
Figure 1. The Role of Site a in Constitutive HLA Class I Expressiontive and IFNg-inducible expression of MHC class II
in B Cells
genes (Chang et al., 1994; Steimle et al., 1994; Lee and
Transient transfection of the HLA-B7 promoter±luciferase reporter
Benveniste, 1996). plasmids (pGL3-B250, pGL3-B140, pGL3-B60, and pGL3-B250Da)
CIITA is also important in the regulation of expression in EBV-transformed B cells. Luciferase activity is shown as mean 6
of invariant chain (Ii), HLA-DMA, and HLA-DMB (Chin et SD (n 5 3).
al., 1994; Chang and Flavell, 1995; Kern et al., 1995),
which, like MHC class II genes, contain X and Y boxes
in which the 6 bp core sequence of site a is deletedwithin the promoter region (O'Sullivan et al., 1986; Kelly
(pGL3-B250Da) didnot result in anysignificant transacti-et al., 1991a). Coordinate expression of these proteins
vation (Figure 1). This strongly suggests that site a fulfillsis essential for MHC class II complex assembly and
a crucial role in cell lines that constitutively expresstranslocation to the cell surface membrane (Germain,
MHC class I.1994; Fling et al., 1994; Sloan et al., 1995).
This study shows that site a is essential for the IFNg-
Site a Is Crucial for IFNg-Inducedinduced transactivation of MHC class I through the ISRE.
Transactivation via the ISREFurthermore, a second route of IFNg-induced transacti-
Transient transfection experiments were conducted invation of MHC class I is revealed, and this route, which
the cervix carcinoma cell line HeLa to determine theis mediated by CIITA, is also dependent on site a. There-
contributions of the different regulatory elements tofore, site a is crucial for both the classic route of IFNg
IFNg-induced MHC class I transactivation. IFNg treat-induction via the ISRE and a novel route of activation
ment of cells transfected with pGL3-B250 gave rise tomediated by CIITA. Furthermore, the identification of
a 4-fold induction of transcription (Figure 2). The impor-CIITA as mediator of this route reveals a direct link be-
tance of site a in IFNg-induced MHC class I transcriptiontween the cytokine-induced activation of MHC class I
was demonstrated using the site a deletion constructand MHC class II gene expression.
pGL3-B250Da, which could not confer IFNg-induced
MHC class I transactivation. As expected, lack of the
ISRE in the HLA-B7 promoter construct pGL3-B140Results
strongly impaired IFNg transcription (Figure 2). Compa-
rable results were obtained with a similar set of reporterConstitutive MHC Class I Expression Requires
the Promoter Element Site a constructs driven by the HLA-A2 promoter (data not
shown). On the basis of these results, it can be con-Several regulatory elements in the MHC class I promoter
have been implicated in constitutive expression. The cluded that site a is crucial for the functioning of the
ISRE, which mediates IFNg-induced HLA class I trans-importance of site a in constitutive expression was eval-
uated by transient transfection experiments in Epstein- activation.
Barr virus (EBV)±transformed B cells, which have a con-
stitutively high expression of MHC class I. Transfection ATF/CREB Family Factors Bind Site a Constitutively
To determine what proteins interact with site a, electro-of luciferase reporter constructs containing promoter
fragments of thehuman MHC class I gene HLA-B7 linked mobility shift assays using nuclear extracts from cell
lines of different cell type origins were performed. Theseto the firefly luciferase gene showed that transactivation
was highest in constructs containing the regulatory ele- assays revealed the binding of several protein com-
plexes to the site a probe in both untreated and IFNg-ments enhancer A, ISRE, and site a (pGL3-B250). Ab-
sence of both enhancer A and the ISRE in the promoter treated HeLa cells (Figure 3). A similar pattern of bands
was found using nuclear extracts from untreated andconstructs (pGL3-B140) resulted in a reduced level of
transactivation when compared to the full-length pro- IFNg-treated teratocarcinoma 2102Ep cells and B cells
(Figure 3). In competition experiments, the complexmoter constructs pGL3-B250 (Figure 1). Reporter con-
structs containing all upstream regulatory elements (en- could be competed for only with the consensus HLA-
B7 site a probe and not with the mutant oligonucleotideshancer A and ISRE) of the HLA-B7 promoter region but
Site a and IFNg-Induced MHC Class I Gene Expression
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Figure 2. Site a Is Crucial for IFNg-Induced Transactivation of HLA
Class I via the ISRE
Transient transfection of reporter constructs, containing HLA-B pro-
moter fragments of decreasing length or mutated in their site a core
sequence (pGL3-B250, pGL3-B140,pGL3-B120, and pGL3-B250Da)
in HeLa cells. Cells were treated with IFNg (500 U/ml) for 24 hr.
Luciferase activity, corrected for transfection efficiency with
b-galactosidase values, is shown as mean 6 SD (n 5 4).
Figure 3. Site a Is Constitutively Bound by Factors of the ATF/CREB
Family of Transcription Factors
Electromobility gel shift assay using a probe of the region containing
(see Experimental Procedures) deleted in the site a core site a of HLA-B7 (see Experimental Procedures) with nuclear ex-
sequence (TGACGC) or containing a mutated site a core tracts (NE) of HeLa, 2102Ep, and EBV-transformed B cells either
sequence (GGACGC) (data not shown), demonstrating untreated or treated with IFNg (2 hr, 500 U/ml).For supershift assays,
an anti-c-Fos antibody (Ab), an anti-c-Jun/AP-1 Ab, and an anti-the specificity of the complex. The nature of the tran-
ATF-1 Ab (see Experimental Procedures) were used as indicated.scription factors that bind to the site a probe was deter-
mined by supershift assays. Since the core sequence
of site a (TGACGC) is homologous to AP-1± and CRE-
and ATF/CREB-like proteins (Anderson and Peterlin,binding sites, antisera directed against the Fos/Jun and
1990; Liou et al., 1990; Ono et al., 1991a, 1991b; CoxATF/CREB families of transcription factors were em-
and Goding, 1992; Moreno et al., 1995).ployed. As is shown in Figure 3, with the use of the
To test whether CIITA could transactivate MHC classanti-ATF-1 antibody (reactive with ATF-1, CREB-1, and
I gene expression, transient transfection experimentsCREM-1), the protein(s) contained in the complexes
were performed in several IFNg-sensitive cell lines. Co-binding site a could be identified as members of the
transfection of the episomal expression vector pREP4-ATF/CREB family of transcription factors. There was no
CIITA with pGL3-B250, resulted in a markedly inducedapparent binding of proteins of the Fos/Jun family of
HLA-B7±driven transcription in HeLa and 2102Ep cellstranscription factors to site a under these conditions,
(Figure 4). Similarly, HLA-A2±driven transcription wasnot even when the complex was first supershifted with
induced by cotransfection of pREP4-CIITA. As expected,the anti-ATF-1 antibody, revealing another band migrat-
HLA-DRA±driven gene transcription was strongly in-ing at similar height (Figure 3). Similar results were found
duced by cotransfection of pREP4-CIITA. HLA-G±drivenin supershift assays using nuclear extracts from 2102Ep
reporter constructs served as a negative control in theseand B cells (data not shown).
experiments, since HLA-G lacks most of the MHC class
I promoter regulatory elements and is insensitive to IFNgCIITA Is a Transactivator of MHC Class I
induction (data not shown; Le Bouteiller, 1994). SimilarAlthough site a was shown to be involved in the IFNg-
results were found in several other cell lines, such as theinduced MHC class I transactivation through the ISRE,
teratocarcinoma cell line Tera-2, the melanoma IGR39D,no additional complex that binds site a could be de-
and SV40-transformed dermal fibroblast cells (data nottected after IFNg induction. This led us to the hypothesis
shown). On the basis of these results, it can be con-that an additional, putative non±DNA-binding protein
cluded that CIITA is capable of transactivating classicwas involved in the IFNg-induced transactivation of
MHC class I genes.MHC class I. For MHC class II transactivation, such a
role had already been assigned to the coactivator CIITA,
which is itself under the control of the IFNg induction Transactivation by CIITA Is Mediated
through Site apathway (Steimle et al., 1993; Steimle et al., 1994). Fur-
thermore, the X2 box in MHC class II promoters, which To determine whether CIITA would be acting via site a,
the HLA-B7 promoter constructs were tested in HeLahas been shown to be important in CIITA-mediated
transactivation of MHC class II genes (Zhou and and 2102Ep cells. As shown in Figure 5, lack of the
enhancer A and ISRE in pGL3-B140 did not influenceGlimcher, 1995), also has binding affinity for Fos/Jun-
Immunity
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Mutated Forms of CIITA That Are Not Functional
in MHC Class II Transactivation Are Unable to
Transactivate MHC Class I
Earlier studies have shown that CIITA contains three
domains involved in transactivation of MHC class II gene
expression (Riley et al., 1995; Zhou and Glimcher, 1995).
These include an N-terminal acidic domain with trans-
activation properties; a proline-, serine-, and threonine-
rich domain;and a C-terminaldomain. To evaluate which
domains of CIITA are essential for MHC class I transacti-
vation, several constructs of CIITA expressing truncated
forms or forms mutated in the C-terminal domain were
tested in cotransfection experiments. The CIITA form
found in cell line RJ2.2.5 (pREP4-CTIIA-RJ), belonging
to the BLS complementation group A, did not manifest
transactivating activity of MHC class I, and neither did
cotransfection of the truncated forms of CIITA, pREP4-
CIITA-N110 and pREP4-CIITA-N410 (Figure 6). This indi-
cates that the N-terminal and the proline-, serine-, and
threonine-rich domains are not sufficient and require in
addition the C-terminal domain for MHC class I trans-
activation.
Figure 4. HLA-A and HLA-B Transcription Is Induced by CIITA
Transient cotransfection of the HLA-DRA, HLA-A2, or HLA-B7 pro-
Only the MHC Class I Heavy Chain Ismoter±luciferase reporter plasmids (pGL3-DRA, pGL3-A230, and
pGL3-B250, respectively) with pREP4-CIITA in HeLa and 2102Ep. Induced by CIITA
HLA-G promoter±luciferase reporter plasmid (pGL3-G220) served To evaluate the potential transcriptional induction of
as a negative control. Relative luciferase activity (3 103) is shown the antigen- processing genes by CIITA, cotransfections
as mean 6 SD (n 5 4) and was calculated as the luciferase activity
were performed with pREP4-CIITA and reporter con-of the test constructs divided by the luciferase activity values of
structs containing the TAP1 or LMP2 promoter region.pGL3-Basic. Luciferase values were corrected for transfection effi-
These transient transfection experiments showed thatciency with b-galactosidase activity.
CIITA was not able to induce either TAP1 or LMP2 tran-
scription in HeLa cells (Figure 7A). To assess the capac-
ity of CIITA to transactivate endogenous MHC class I,the ability of CIITA to transactivate HLA-B7±driven tran-
scription. However, absence of the promoter region be- TAP, and LMP genes, stably CIITA-transfected HeLa
and 2102Ep cells were generated. Pools of hygromycin-tween 2140 and 2120 bp upstream of the transcription
start (containing site a) resulted in a complete loss of resistant colonies were analyzed by immunofluores-
cence for HLA-DR cell surface expression, and the MHCCIITA-induced expression (pGL3-B120; Figure 5). In ad-
dition, the site a mutant construct pGL3-B250Da could class II±positive cells among these primary pools were
enriched for by cell sorting and then used for furthernot be transactivated by CIITA (Figure 5). Comparable
results were obtained with a similar set of reporter con- analysis. A semiquantitative reverse transcriptase poly-
merase chain reaction (RT-PCR) assay was used tostructs driven by the HLA-A2 promoter (data not shown).
From these experiments it can be concluded that site determine the level of CIITA transcripts in these stably
transfected cells. In the CIITA-transfected cells, a higha is crucial for MHC class I gene transactivation by
CIITA. level of CIITA transcripts could be detected, and this
Figure 5. Site a Is Crucial in CIITA-Mediated
Transactivation of HLA Class I
Transient cotransfection in HeLa and 2102Ep
cells of pREP4-CIITA with reporter con-
structs, containing HLA-B7 promoter frag-
ments of decreasing length or mutated in
the site a core sequence. Luciferase activity,
corrected for transfection efficiency with
b-galactosidase values, is shown as mean 6
SD (n 5 4).
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Values are calculated as the ratio of the normalized densitometric
values of CIITA-transfected cells over those of mock-transfected
cells. Densitometric values were normalized to the corresponding
GAPDH values and were derived from the Northern blots shown in
Figure 6. Mutated Forms of CIITA That Are Not Functional in HLA Figure 7C.
Class II Transactivation Are Unable to Transactivate HLA Class I
The capacity of the deleted CIITA form of RJ2.2.5 or truncated
CIITA forms to transactivate HLA class I was tested by transient MHC class II positive, and the same heterogeneity was
cotransfection with the HLA-B7 promoter±driven luciferase reporter
seen for the elevated level of MHC class I expressionplasmids. HLA-DRA promoter constructs served as a control. Lucif-
(Figure 8).erase activity, corrected for transfection efficiency with b-galactosi-
dase values, is shown as mean 6 SD (n 5 4).
Discussion
The expression of MHC class I genes is tightly regulatedlevel increased only slightly upon IFNg treatment; in the
mock-transfected cells, CIITA transcripts were difficult both during development and also in fully differentiated
cells. Control at the transcriptional level is determined byto detect in noninduced cells but were markedly in-
creased after IFNg treatment (Figure 7B). Northern blot various regulatory elements in theMHC class Ipromoter.
Site a, positioned 2130 bp upstream of the transcriptionanalysis revealed that the CIITA-transfected cells dis-
played an induced level of endogenous MHC class I and start site, is highly conserved among the various MHC
class I loci, with the exception of HLA-G (Dey et al.,class II transcripts (Figure 7C and Table 1). In contrast,
b2m, TAP1, TAP2, LMP2, and LMP7 genes displayed no 1992; Ting and Baldwin, 1993; Le Bouteiller, 1994). The
exact role of site a in MHC class I transcriptional controlsignificant increase in the level of transcription in CIITA-
transfected cells (Figure 7C and Table 1). The increased has hitherto been poorly defined. It has been shown
that site a, together with other regulatory elements, con-level of MHC class I transcription was also reflected in
an increased expression of MHC class I heavy chain tributes to the constitutive expression of MHC class I
in lymphoid cells (Dey et al., 1992; Baeuerle and Henkel,protein, as determined by Western blot analysis (Fig-
ure 7D). 1994; Le Bouteiller, 1994; this study). The core sequence
of site a (TGACGC) present in HLA-B, HLA-C, HLA-E,
and HLA-F (C/GGACGC in HLA-A) is homologous toCIITA Can Enhance the Level of MHC Class I
Cell Surface Expression CRE- or AP-1± binding sites, and it has been speculated
that proteins of the Fos/Jun or ATF/CREB family of tran-Since only MHC class I heavy chain was induced by
CIITA and since the genes that encode molecules in- scription factors bind to this site (Korber et al., 1988;
IsraeÈ l et al., 1989; Dey et al., 1992). In this study, it couldvolved in antigen processing and assembly of MHC
class I molecules were not, we evaluated possible be demonstrated that in both lymphoid and non-
lymphoid cells, members of the ATF/CREB family ofchanges in cell surface expression in an extended panel
of CIITA-transfected cells. The level of MHC class I and transcription factors do indeed bind site a and do so in
a constitutive manner. Binding by proteins of the Fos/class II cell surface expression was determined by fluo-
rescence-activated cell sorter analysis (Figure 8). Ex- Jun family of transcription factors could not be detected
under these conditions. In view of these findings, it ispression of theexogenous CIITA gene resulted ina negli-
gible increase in the level of MHC class I cell surface noteworthy that the X2 box in MHC class II promoters,
which has been shown to be important in CIITA-medi-expression on HeLa, 2102Ep, and WSI (fibroblast) cells,
whereas cell surface expression of MHC class II was ated transactivation of MHC class II genes (Zhou and
Glimcher, 1995), also has binding affinity for ATF/CREB-clearly induced (Figure 8). In contrast, CIITA had a
marked effect on the level of MHC class I cell surface like proteins (Anderson and Peterlin, 1990; Liou et al.,
1990; Ono et al., 1991a; Cox and Goding, 1992; Morenoexpression in several other cell lines (the chronic my-
elogenous leukemia cell line K562, the fibroblast cell et al., 1995).
The IFNg induction of MHC class I genes is known toline ATU, and the fibrosarcoma cell line G3A; see Experi-
mental Procedures). A significant increase in the level be mediated through binding of the transactivator IRF-1
to the ISRE (Chang et al., 1992; Girdlestone et al., 1993;of MHC class I molecules expressed at the cell surface
was observed in CIITA- transfected K562, ATU, and G3A Johnson and Pober, 1994; unpublished data). Here, it
is shown that site a is crucial for this classic route ofcells (Figure 8).The population of CIITA-transfected G3A
cells was heterogeneous: about 50% of the cells were IFNg-induced MHC class I gene expression. However,
Immunity
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Figure 7. CIITA Induces Endogenous HLA Class I Expression but
Does Not Induce Genes Involved in Antigen Processing and Assem-
bly of MHC Class I Molecules
(A) Transient cotransfection of the HLA-B7, TAP1, and LMP2 pro-
moter±luciferase reporter plasmids (pGL3-B250, pGL3-TAP1, and
pGL3-LMP2, respectively) with pREP4-CIITA in HeLa. Both pGL3-
TAP1 and pGL3-LMP2 reporter plasmid could be induced by IFNg
(2- to 5-fold induction; data not shown). Luciferase activity, cor-
rected for transfection efficiency with b-galactosidase values, is
shown as mean 6 SD (n 5 4).
(B) Total RNA derived from CIITA- or mock-transfected cells of HeLa
and 2102Ep was subjected to RT-PCR amplification using CIITA-
specific primers. Amplification using GAPDH-specific primers was
performed as a control. The PCR products of 35 cycles of amplifica-
tion were size-fractionated on a 1.5% agarose gel.
(C) The effect of CIITA on the expression of HLA-DRA, HLA class I,
b2m, TAP1, TAP2, LMP2, and LMP7 as determined by Northern blot
analysis. The cells were either untreated or treated with IFNg (500
U/ml for 48 hr). The level of GAPDH expression was used as a
measure of the relative RNA content in each lane.
(D) Induced HLA class I heavy chain expression in CIITA-transfected
HeLa and 2102Ep cells, as determined by Western blot analysis.
The level of actin expression was used as a measure of the relative
protein content in each lane.
no new DNA-binding complex could be detected bind- site a mediates transactivation by CIITA and is therefore
also crucial for this pathway of transactivation. Similaring site a after IFNg treatment. Site a, which is shown
to be constitutively occupied, may allow interaction be- results are found for the mouse MHC class I promoter
(Martin et al., 1997 [Immunity, this issue]).tween proteins of the IRF family binding the ISRE and
proteins of the ATF/CREB family binding site a. The CIITA contains three domains essential for transacti-
vation of MHC class II: an N-terminal acidic domainprotein complex binding site a may also facilitate inter-
actions with a coactivator. In this study, it is shown that with transactivation properties; a proline-, serine-, and
threonine-rich domain; and a C-terminal domain (RileyCIITA, which originally was described as a transcrip-
tional coactivator specific for genes involved in MHC et al., 1995; Zhou and Glimcher, 1995). Mutation analysis
has shown that the N-terminalacidic domain is essentialclass II±mediated antigen presentation, is also capable
of up-regulating MHC class I expression in human (tu- for general transcription activation of MHC class II; the
proline-, serine-, and threonine-rich domain is requiredmor) cell lines of various tissue origin. Therefore, CIITA
represents a direct link between IFNg-induced MHC for optimal transcriptional activity; and the C-terminal
domain is essential for specific interactions with MHCclass I and class II gene regulation. In mutational analy-
sis of the MHC class I promoter region, it was found that class II transcription regulators. Because the truncated
Site a and IFNg-Induced MHC Class I Gene Expression
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remain unchanged and could therefore become limiting.
To induce the level of MHC class I cell surface expres-
sion in these cells, other components of the IFNg induc-
tion pathway would be needed for a concommitant in-
duction of the b2m, TAP, or LMP genes. In contrast, in
cell lines in which the cell surface expression is limited
by low levels of MHC class I heavy chain expression,
CIITA is able to enhance the level of MHC class I cell
surface expression. This is best illustrated in the MHC
class I heavy chain±deficient K562 (Sutherland et al.,
1985; Chen et al., 1986; Blanchet et al., 1991), in which
CIITA was able to restore MHC class I cell surface ex-
pression. In addition, cell lines such as G3A (Chin et al.,
1994) and ATU (BLS fibroblast cell line; A. P. et al.,
unpublished data), in which the level of MHC class I
heavy chain is reduced, also displayed a marked in-
crease inMHC class Icell surface expression upon CIITA
transfection.
Transcriptional gene expression isgenerally regulated
by a number of transactivating factors acting in concert.
Therefore, lack of one transcription factor may be of
influence but could be compensated by others. For the
recently generated CIITA2/2 knockout mice (Chang et
al., 1996), it was not reported whether the constitutive
and IFNg-induced level of MHC class I expression in the
different cell types tested was similar to that in wild-
type mice, but if so, this could be an example of such
compensation by other (related) transcription factors.
In this respect, the complete dependency of MHC class
II gene expression on one transactivator is more likely
an exception than a rule.
Taking all of these findings into account, we propose
a new model for IFNg-induced transactivation of MHC
Figure 8. CIITA Can Enhance the Level of MHC Class I Cell Surface class I, in which site a plays a central role (Figure 9).
Expression This pathway is initiated by activation of factors of the
The level of HLA class II and class I cell surface expression on JAK/STAT pathway by the binding of IFNg to its receptor
CIITA-transfected HeLa, 2102Ep, WSI, K562, ATU, and G3A cells (Darnell et al., 1994; Schindler and Darnell, 1995). This
was determined by fluorescence-activated cell sorter analysis. Filled
results in the induction or activation of transcription fac-and open profiles represent CIITA- and mock-transfected cells, re-
tors of the IRF family (such as IRF-1), which bind thespectively.
ISRE and transactivate MHC class I genes (Ting and
Baldwin, 1993; Le Bouteiller, 1994). Although this path-
forms of CIITA tested were unable to transactivate MHC way is dependent on site a, it is not clear at this time
class I, it is very possible that all three domains are whether this is the result of interactions between the
required and carry out a similar function in the transcrip- transcription factors occupying both regulatory ele-
tional regulation of both MHC class I and class II. This ments. The observed induction of endogenous CIITA
is supported by evidence from a detailed structural do- expression by IFNg and the enhancedlevel of MHC class
main analysis by Martin et al. (1997). I expression in CIITA-transfected cells strongly suggest
The results presented here demonstrate that CIITA a parallel activation route for IFNg-induced MHC class
induces MHC class I gene transcription, leading to in- I gene expression. In this second route, the activation
creased levels of MHC class I heavy chain protein. How- of the JAK/STAT pathway leads to the induced expres-
ever, it was shown that CIITA had no apparent regulatory sion of CIITA (Steimle et al., 1994; Lee and Benveniste,
effect on the expression of b2m and the antigen-pro- 1996; Meraz et al., 1996). CIITA could actuate an in-
cessing genes important for MHC class I±mediated anti- crease in MHC class I heavy chain expression by acting
gen presentation at the cell surface, which is in as a coactivator, presumably interacting with the ATF/
agreement with findings by Martin et al. (1997). This may CREB transcription factors occupying site a. This hy-
explain why the observed induced level of transcription pothesis is supported by the observation that deletion
of the MHC class I heavy chain gene in the CIITA- of the site a core sequence abrogates transactivation
transfected cells did not result in a significant increase in by CIITA. Under these experimental conditions, site a
cell surface expression in HeLa, 2102Ep, and fibroblast is apparently not dependent on the ISRE and its binding
cells. It can be envisaged that in these cells the CIITA- proteins to mediate transactivation by CIITA, because
induced MHC class I heavy chain expression is not suffi- promoter constructs lacking elements upstream from
cient to induce class I cell surface expression because site a are still activated by CIITA. Whether CIITA itself
can transactivate the basal transcription complex or isthe levels of expression of the b2m, TAP, or LMP genes
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is derived from a BLS patient and is characterized by a lack of (IFNg-
induced) MHC class II cell surface expression, which can be restored
upon CIITA transfection (A. P. et al., unpublished data). All cells were
grown in Iscove's modified Dulbecco's modified minimal essential
medium supplemented with 10% (v/v) heat-inactivated fetal calf
serum (Gibco, Paisley, Scotland), penicillin (100 IU/ml), and strepto-
mycin (100 mg/ml). Recombinant human IFNg (Boehringer-Ingel-
heim, Ingelheim, Germany) was used at a concentration of 500 U/ml.
Plasmids
The episomal expression vector construct pREP4-CIITA contains
the 4.5 kb CIITA cDNA fragment (Steimle et al., 1993) cloned in the
XhoI site of pREP4 (Invitrogen, San Diego, CA). The expression of
CIITA is driven by promoter sequences from the Rous sarcoma virus
long terminal repeat. The truncated CIITA constructs pREP4-CIITA-
N110 and pREP4-CIITA-N410 contain a 445 bp NotI±PvuII and 1345
bp NotI±NotI fragment of pREP4-CIITA, respectively. A mutated
CIITA form present in the cell line RJ2.2.5 of BLS complementation
group A was generated by PCR amplification (forward primer ATG
GCTAGCGATTCCTACACAATGCGTTGCCTGGCTC, reverse primer
ATGCTCGAGCAAGGTCCAGCGTGGTTAGTGTCCTCAG; Riley et
al., 1995). The PCR±amplified cDNA fragments were cloned into
pREP4/NheI±XhoI to give rise to pREP4-CIITA-RJ.
Reporter constructs were all based on the luciferase reporter
plasmid pGL3-Basic (Promega, Madison, WI) and contained either
a 294 bp XbaI±SacI HLA-DRA promoter fragment (pGL3-DRA), a
230 bp BglI±AhaII HLA-A2.1 promoter fragment (pGL3-A230), a 140
bp PpuMI±AhaII HLA-A2.1 promoter fragment (pGL3-A140), a 120
bp AvaII±AhaII HLA-A2.1 promoter fragment (pGL3-A120), a 268
bp AspI±AhaII HLA-B7 promoter fragment (pGL3-B250), a 140 bp
PpuMI±AhaII HLA-B7 promoter fragment (pGL3-B140), a 120 bp
MluI±AhaII HLA-B7 promoter fragment (pGL3-B120), a 60 bp XbaI±
AhaII HLA-B7 promoter fragment (pGL3-B60) or a 220 bp HLA-G
Figure 9. Model for IFNg-Induced MHC Class I Gene Transcription promoter PCR fragment (pGL3-G).
Regulation Site a mutant constructs, deleted in the 6 bp core sequence,
In the proposed model, the classic route of IFNg induction via the were generated by site-directed mutagenesis using the overlapping
ISRE and the new route of activation mediated by CIITA are merged extension method (Ho et al., 1989). Primers used for amplification
by a mutual dependency on site a. The classic route by which the of HLA-A2 promoter fragments were AA2: 59-GATAGATCTCAGGCC
induced oractivated transcription factors of the interferon regulatory CCGAAGGC; BA2: 59-ACTGGGTCCTGAGTATCCAGGAAGAAGGA;
factor family (such as IRF-1) bind the ISRE and transactivate MHC CA2: 59-TGGATACTCAGGACCCAGTTCTCACTCC; and DA2: 59-GAT
class I genes is paralleled by a second route by which the IFNg- AAGCTTCGGCGTCTGGGGAGAAT. Primers used for amplification
induced expression of CIITA actuates an increase of MHC class I of HLA-B7 promoter fragments were AB7: 59-GATAGATCTCAGGAC
heavy chain expression by acting as a coactivator possibly inter- GAAGTCCCAGG; BB7: 59-AAGTGGGGACGAGTATCCTAGAAGAA
acting with the ATF/CREB transcription factors that occupy site a. GGA; CB7:59- AGGATACTCGTCCCCACTTCCCACTCC; and DB7:
59-GATAAGCTTCGGCGTCTGAGGAGACT. First, two separate PCR
fragments were generated (25 cycles at 958C for 1 min, 528C for 1
min, and 728C for 1 min) with primer sets A/B and C/D. Next, themerely an activator of site a±binding factors in MHC
two products were annealed by virtue of overlapping sequences inclass I transactivation remains to be determined.
primers B and C, and a second PCR amplification was performedIn conclusion, it is shown that site a is essential for
on the elongated template (35 cycles at 958C for 1 min, 508C for 1.5
the IFNg-induced transactivation of MHC class I through min, and 728C for 1 min) using primer set A/D. The PCR fragments
the ISRE. In addition, this report provides evidence for were digested at their introduced BglII and HindIII sites and ligated
into the BglII and HindIII sites of pGL3-Basic (Promega). All plasmidsa second site a±dependent pathway of IFNg-induced
were verified by sequence analysis (T7-polymerase sequence kit;activation of MHC class I genes. This new route of trans-
Amersham, Buckinghamshire, England).activation mediated by CIITA is the first direct link be-
Reporter constructs containing the TAP1 or LMP2 promoter usedtween MHC class I and MHC class II gene activation.
were pGL3-Enhancer vector-based plasmids (a kind gift from Dr.
Site a is therefore crucial for both the classic route of B. Seliger, III Medizinische Klinik, J. Gutenberg UniversitaÈ t Mainz,
IFNg inductionvia the ISRE and the novel route of activa- Germany) as well as the CAT reporter plasmids (a kind gift from Dr.
J. P.-Y. Ting; Wright et al., 1995).tion mediated by CIITA.
Experimental Procedures Transient Transfection
The EBV-transformed B-cells (5 3 106) were transfected by electro-
poration (300 V, 960 mF; Genepulser, Bio-Rad Laboratories, CA) withCell Culture
Cell lines used in this study were the human cervical carcinoma cell 20 mg pGL3 reporter plasmid and harvested 40 hr after transfection.
Adherent cells were transfected by thecalcium phosphate coprecip-line HeLa, the teratocarcinoma cell line 2102Ep (Andrews et al.,
1987), the teratocarcinoma cell line Tera-2, the melanoma cell line itation method (Chen and Okayama, 1987). In each of four wells in
a six-well plate, 0.25 3 106 cells were transfected with 2.5 mg pGL3IGR39D (a kind gift from Dr. P. I. Schrier; Versteeg et al., 1988), an
EBV-transformed B cell line (MBW), the SV40-transformed fibroblast reporter plasmid, 6.25 mg of either pREP4 or pREP4-CIITA, and
2.5 mg pRSVLacZ plasmid (Promega) and harvested 40 hr aftercell line WSI, the chronic myelogenous leukemia cell line K562, the
in vitro generated mutant fibrosarcoma cell line G3A (a kind gift transfection. For dose-response experiments, 0.5 mg pGL3 reporter
plasmid was cotransfected with various concentrations of pREP4-from Dr. J. P.-Y. Ting; Chin et al., 1994), and the SV40-transformed
fibroblast cell line ATU (a kind gift of Dr. OÈ . Sanal). The cell line ATU CIITA (2.44 ng to 20 mg) supplemented with pREP4 to a final amount
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of 20 mg, and 2.5 mg pRSVLacZ control plasmid. The pGL3-based transfected with pREP4 (mock-transfected cells) were used as a
reporter constructs were linearized prior to transfection. Luciferase negative control. Subconfluent cultures of the CIITA- or mock-
activity was determined using a luminometer (Tropix, Bedford, MA) transfected cells were stainedby indirect immunofluorescence, with
and corrected for b-galactosidase activity and is shown as mean 6 an anti-HLA-DR monoclonal antibody or the anti-MHC class I mono-
standard deviation (SD). In some experiments, the luciferase values clonal antibody W6/32 as first antibody and anti-mouse IgG as sec-
are expressed as relative luciferase activity, which is the luciferase ond antibody (Becton-Dickinson). The analysis was performed on
activityof the promoter-containing constructs divided by the luciferase a FACScan flow cytometer (Becton-Dickinson) using FACScan and
activity value of pGL3-Basic and which is shown as mean 6 SD. LYSIS software.
The MHC class II±positive cells in the CIITA-transfected pool were
Preparation of Nuclear Extracts enriched for by cell sorting using either a FACSTAR flow cytometer
Nuclear extracts were prepared from 10 3 106 cells. The cells were (Becton-Dickinson) or Dynabeads coated with sheep anti-mouse
harvested, washed with phosphate-buffered saline and taken up in IgG as second antibody (Dynal AS, Oslo, Norway). Pools of the cell
300 ml (three cell volumes) of hypotonic solution (20 mM HEPES [pH lines transfected with pREP4 (mock-transfected cells) served as a
8.0], 10 mM KCl, 0.15 mM EGTA, 0.15 mM EDTA, 1 mM dithiothreitol negative control.
[DTT], 0.5 mM AEBSF) and were left on ice for 15 min. The cells
were lysed with NP-40 (final concentration of 0.1% for B cells, 0.2%
RT-PCR Assayfor 2102Ep, and 0.4% for HeLa) for 3±5 min. Eighty microliters (80%
For semiquantitative RT-PCR analysis, total RNA was isolated withof the cell volume) of a sucrose solution (50 mM HEPES [pH 8.0],
RNAzol (Cinna/Biotecx Laboratories, Houston, TX) following the10 mM KCl, 0.25 mM EDTA, 1 mM DTT, 0.5 mM AEBSF, 70% w/v
manufacturer's instructions. First strand cDNA was synthesized insucrose) was added, and the nuclei were centrifuged cold at 5000
the presence of random hexamer (Pharmacia) using the Riboclonerpm for 5 min. The supernatant was discarded and the pellet was
cDNA Synthesis System (Promega) according to the manufacturer'sgently taken up in 300 ml (three cell volumes) of solution B (10 mM
instructions. Semiquantitative PCR was performed in the linearHEPES [pH 8.0], 100 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mM
phase of amplification by testing PCR products after varying num-AEBSF, 25% v/v glycerol) and centrifuged at 48C at 5000 rpm for 5
bers of cycles. For the PCR, 1 ml of cDNA sample was used in amin. After the supernatant was discarded, the cell pellet was taken
total reaction volume of 100 ml containing 10 mM Tris-HCl [pH 8.4],up in 200 ml (two to three cell volumes) of extraction solution (10
mM HEPES [pH 8.0], 400 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.5 50 mM KCl, 4 mM MgCl2, 0.6 mg/ml BSA, 0.5 mM of each dNTP, 20
mM AEBSF, 25% glycerol) and left on ice for 30 min with intermittent pmol of 59 primer, and 20 pmol of 39 primer. The following primer
vortexing. The extracted nuclei were centrifuged at 48C at 14,000 pairs were used: CIITA, sense 59-GCTTGTGGCCGGCTTCCCCAGT
rpm for 5 min, and the supernatant was aliquoted and stored at and anti-sense 59-TGGAAGATCAGCCCAGCCAGAAAGC; glyceral-
2808C. dehyde-3-phosphate dehydrogenase (GAPDH), sense 59-GGTCGG
AGTCAACGGATTTG and anti-sense 59-ATGAGCCCCAGCCTTCTC
Electromobility Gel Shift Assay CAT. The samples were heated to 958C for 2 min and cooled to
Nuclear extracts (about 5 mg) were incubated in binding buffer (20 858C, at which point 2.5 U AmpliTaq DNA polymerase was added
mM HEPES [pH 7.9], 50 mM KCl, 10% v/v glycerol, 0.5 mM DTT, (Perkin-Elmer Cetus, Emeryville, CA), and the PCR amplification was
0.1 mM EDTA, 1 mg poly(dI-dC), and 1 mg sonicated single-stranded run for 10, 20, 30, or 40 cycles (1 min at 948C, 1 min at 608C, and
herring sperm DNA) with 1 ng [32P]-radiolabeled probe for 15 min at 1.5 min at 728C). The PCR products, 15 ml for CIITA samples and 5
48C. The samples were run on a 6% polyacrylamide gel in 0.253 ml for GAPDH samples, were size fractionated on an 1.5% agarose
TBE buffer at 200 V for 2 hr. The gels were fixed and dried onto gel, transferred to a Hybond N1 nylon membrane (Amersham), and
Whatman paper and exposed to X-ray film. The double-stranded subsequently hybridized with 32P-labeled human CIITA (Steimle et
oligonucleotide representing HLA-B7 site a (GGATACTCGTGACGC al., 1993) or GAPDH probes (Versteeg et al., 1988), to verify the
GTC) was used as a probe. amplified products. Half of the total RNA of each sample was sub-
Competition experiments were performed with the HLA-B7 site a jected to the same protocol but without reverse transcriptase in the
probe and two different mutant oligonucleotides: B7Da, which has reaction mixture, to serve as a control for DNA contamination.
a 6 bp mutation of the site a core sequence (AGGATACTCGTCCCCA
CTTCCCACTCC), or B7aA3, which contains a variant of the site a
Northern Blot Analysiscore sequence (TACTCGCGGACGCGTCC) present in HLA-A3. Each
Total RNA was isolated from subconfluent cultures by the RNAzol(cold) double-stranded oligonucleotide was added at 503, 1003,
extraction method (Cinna/Biotecx Laboratories). RNA samples (20and 2003 excess before incubation with radiolabeled HLA-B7 site
mg/lane) were run on a 1.2% agarose gel containing 2.2 M formalde-a probe.
hyde, transferred to a Hybond N membrane (Amersham), and hybrid-In supershift assays, 1 mg of each antibody directed against mem-
ized with 32P-labeled probes (random priming; DuPont±NEN, Boston,ber of the Fos/Jun or ATF/CREB family of transcription factors were
added to nuclear extracts and probe mixture and incubated over- MA) for HLA-DRA (Marcadet et al., 1987), HLA class I (Sood et al.,
night at 48C. The anti-c-Fos antibody (sc-413) is broadly reactive 1981; Marcadet et al., 1987), b2m (Gussow et al., 1987), TAP1 (Spies
with c-Fos, Fos B, Fra-1, and Fra-2; the anti-c-Jun/AP-1 antibody et al., 1990), TAP2 (Bahram et al., 1991), LMP2 (Kelly et al., 1991b),
(sc-44) is broadly reactive with c-Jun, Jun B, and Jun D; and the LMP7 (Glynne et al., 1991), and b-actin (Cleveland et al., 1980). For
anti-ATF-1 antibody (sc-270) is reactive with ATF-1, CREB-1, and quantitation, the autoradiograms were scanned using an Eagle Eye
CREM-1 (Santa Cruz Biotechnology, Santa Cruz, CA). II apparatus and Eagle Sight 3.0 image-capture and analyzing soft-
ware (Stratagene, La Jolla, CA).
Generation of Stable Cell Lines Transfected
with pREP4-CIITA
Western Blot AnalysisAdherent cell lines were transfected according to the calcium phos-
Cells (5 3 106) were harvested in lysis buffer (0.5% [v/v] NP-40, 50phate coprecipitation method (Chen and Okayama, 1987), and the
mM Tris-HCl [pH 7.9], 150 mM NaCl, 5 mM EDTA, 2 mM PMSF),nonadherent cell line K562 was transfected with the lipofectin Tfx-50
and the content of solubilized protein in the lysates was determined(Promega) according to the manufacturer's recommendations. The
(BCA protein assay kit; Pierce, Rockford, IL). Protein extracts (500cells were transfected with either pREP4-CIITA or control plasmid
ng/lane) were separated on a 10% SDS polyacrylamide gel, trans-and were grown on selection medium. After selection on 100 mg/ml
ferred to a PVDFtransfer membrane (Polyscreen; NEN, Boston, MA).(HeLa) or 50 mg/ml (2102Ep) Hygromycin B (Boehringer Mannheim,
The proteins were immunostained with anti-MHC class I heavy chainMannheim, Germany) for approximately 2 weeks, hygromycin-resis-
antibody (HC, 1:1000; Neefjes and Ploegh, 1988) or anti-actin anti-tant colonies were pooled.
body (1:1000; Sigma Chemical, St. Louis, MO) followed by horserad-
ish peroxidase±conjugated anti-IgG antibodies. The blots were de-Flow Cytometric Analysis and Cell Sorting
veloped using an enhanced chemoluminescence Western blottingThe MHC class II positive cells in the CIITA-transfected pool (5%±
detection system (Amersham) according to the manufacturer's rec-10%) were enriched for by cell sorting using a FACSTAR flow cyto-
meter (Becton-Dickinson, Mountain View, CA). Pools of the cell lines ommendations.
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